Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of “Moderate Buy” by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $7.00.

Several research firms have recently weighed in on PYXS. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Pyxis Oncology in a report on Tuesday. Wall Street Zen lowered shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Sunday, March 15th. Stifel Nicolaus cut their price objective on shares of Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Finally, Royal Bank Of Canada lowered their target price on Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Thursday, December 18th.

Pyxis Oncology News Roundup

Here are the key news stories impacting Pyxis Oncology this week:

• Positive Sentiment: Quarterly results beat expectations — PYXS reported a loss per share of ($0.29) vs. consensus ($0.35) and generated $11.04M of revenue, showing better-than-expected near-term performance. This beats helped validate recent operations and may support longer-term valuation recovery. Earnings Press Release
• Positive Sentiment: Clinical progress — Pyxis completed target enrollment in the Phase 1 monotherapy dose‑expansion of MICVO (micvotabart pelidotin) in 2L+ R/M HNSCC in Q1 2026. Completion of enrollment advances a near‑term clinical catalyst (data/readout) that could materially move the stock if results are positive. Business Update
• Positive Sentiment: Analyst support remains — HC Wainwright reaffirmed a “buy” rating with a $7 price target, signaling ongoing institutional conviction in the story despite the low share price. HC Wainwright Note
• Neutral Sentiment: Short-interest reporting appears anomalous — multiple March filings list 0 shares short and 0.0 days-to-cover (with NaN changes), suggesting a likely data/reporting issue rather than a meaningful shift in short positioning. Treat this as unreliable until corrected by official exchanges.
• Negative Sentiment: Price target cut by a covering analyst — Stifel Nicolaus lowered its target from $9.00 to $8.00 (but kept a “buy” rating). A lower target, even with a buy rating, can pressure sentiment and weigh on the stock in the near term. Stifel Note

Pyxis Oncology Price Performance

NASDAQ:PYXS opened at $1.36 on Wednesday. The business’s 50-day simple moving average is $1.52 and its 200-day simple moving average is $2.51. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.55. The stock has a market capitalization of $84.67 million, a PE ratio of -1.05 and a beta of 1.45.

Pyxis Oncology (NASDAQ:PYXS) last posted its earnings results on Tuesday, March 24th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The business had revenue of $11.04 million for the quarter. On average, research analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. J. Derek Lewis & Associates Inc. acquired a new stake in Pyxis Oncology in the 4th quarter valued at approximately $61,000. XTX Topco Ltd boosted its position in Pyxis Oncology by 1,533.0% during the 4th quarter. XTX Topco Ltd now owns 289,033 shares of the company’s stock worth $332,000 after acquiring an additional 271,334 shares during the last quarter. Toronto Dominion Bank bought a new position in shares of Pyxis Oncology during the 4th quarter worth approximately $86,000. Quadrature Capital Ltd bought a new position in shares of Pyxis Oncology during the 4th quarter worth approximately $116,000. Finally, Maia Wealth LLC acquired a new stake in shares of Pyxis Oncology in the fourth quarter valued at approximately $25,000. 39.09% of the stock is currently owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.